Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. LMNL

Healthcare Biotechnology
Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Liminal BioSciences Inc.
Bullboard Posts
User Avatar Image
(0)
•••
Comment by Atomekon Dec 01, 2016 10:24am
170 Views
Post# 25539769

RE:RE:Top 20 TSX Filers Past 7 Days Issuers with Net Buying

RE:RE:Top 20 TSX Filers Past 7 Days Issuers with Net Buying
Latest 6 months of SEDI filings for PLI by transaction date, descending ?
Amended Filing
As of 11:59pm ET November 30th, 2016
Filing
Date		 Transaction
Date		 Insider Name Ownership
Type		 Securities Nature of transaction Volume or Value Price
Nov 30/16 Nov 29/16 Thomvest Asset Management Inc. Indirect Ownership Common Shares 10 - Acquisition in the public market 2,499,800 $2.40
Nov 30/16 Nov 29/16 Clulow, Kurt Stefan Victor Control or Direction Common Shares 10 - Acquisition in the public market 2,499,800 $2.40
Nov 30/16 Nov 29/16 Hakim, Raymond Manuel Direct Ownership Common Shares 10 - Acquisition in the public market 25,000 $1.81
USD
Nov 30/16 Nov 29/16 Hakim, Raymond Manuel Direct Ownership Common Shares 10 - Acquisition in the public market 5,000 $1.79
USD
Nov 25/16 Nov 25/16 Mnard, Louise Direct Ownership Common Shares 10 - Acquisition in the public market 10,000 $2.47
Nov 24/16 Nov 24/16 Laurin, Pierre Indirect Ownership Common Shares 10 - Acquisition in the public market 21,600 $2.45
Nov 24/16 Nov 23/16 Laurin, Pierre Indirect Ownership Common Shares 10 - Acquisition in the public market 28,400 $2.48
Nov 25/16 Nov 22/16 Moran, John Edward Direct Ownership Common Shares 57 - Exercise of rights 27,579 $1.71
Nov 25/16 Nov 22/16 Moran, John Edward Direct Ownership Units d'actions restreintes / Restricted Share Units 57 - Exercise of rights -27,579 $1.71
Nov 25/16 Nov 22/16 Booth, Jonathan Direct Ownership Common Shares 57 - Exercise of rights 10,000 $1.71

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities